Treatment of Metastatic Malignant Melanoma with Dacarbazine, Vindesine, and Cisplatin
Author Information
Author(s): D. Pectasides, H. Yianniotis, N. Alevizakos, D. Bafaloukos, V. Barbounis, J. Varthalitis, M. Dimitriadis, A. Athanassiou
Primary Institution: First Department of Medical Oncology, The Metaxas Memorial Cancer Hospital
Hypothesis
Combining dacarbazine, vindesine, and cisplatin will improve response rates in patients with metastatic malignant melanoma.
Conclusion
The combination of dacarbazine, vindesine, and cisplatin produces a relatively high response rate in patients with advanced metastatic malignant melanoma, but the responses are short-lived.
Supporting Evidence
- 19% of patients had a complete response to the treatment.
- 26% of patients had a partial response.
- The total response rate was 45%.
- Responses were more common in patients with lung, lymph node, and subcutaneous metastases.
- The median duration of complete response was 4 months.
Takeaway
Doctors tried a mix of three medicines to help people with a serious skin cancer, and some got better, but it didn't last long.
Methodology
Patients received a combination of cisplatin, vindesine, and dacarbazine over several months, with doses adjusted based on side effects.
Limitations
The study had a small sample size and responses to treatment were short-lived.
Participant Demographics
14 males and 13 females, mean age 54 years.
Want to read the original?
Access the complete publication on the publisher's website